Study of nasopharyngeal bacterial flora. Second report. Variations in nasopharyngeal bacterial flora in children aged 6 years or younger when administered antimicrobial agents. Part 2.
This report focuses on changes in the nasopharyngeal bacterial flora before and after administration of antimicrobial agents in 172 cases of acute upper respiratory infection in patients aged 6 years or younger. The antimicrobial agents administered were amoxicillin (AMPC) (34%), clavulanic acid/amoxicillin compound (11%), cefditren pivoxil (CDTR-PI) (43%), and others (12%). Changes in nasopharyngeal bacterial flora were investigated with reexaminations conducted after 2-5 days (day 2-5 subgroup), 6-10 days (day 6-10 subgroup), and 11 days and thereafter. There was a significant reduction in the Streptococcus pneumoniae detected in the group administered AMPC (AMPC group) in the day 2-5 subgroup and the day 6-10 subgroup. There was also a significant decrease in H. influenzae in the group administered CDTR-PI (CDTR-PI group) in the day 2-5 subgroup. From this it was inferred that for the most part significant changes in infectious nasopharyngeal bacteria occurred in the day 2-5 subgroups. However, a significant improvement in the degree of inflammation, as indicated by leukocyte infiltration images for the AMPC group, was observed in the day 2-5 subgroup, and for the CDTR-PI group in the day 6-10 subgroup. On the other hand, in both the antimicrobial agent groups, S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis were newly detected at reexamination. Furthermore, a difference in the incidence of these bacteria was observed between the 2 antimicrobial agent groups. It was suggested that such phenomena related to the survival of resistant strains or a recurrence otitis media.
Konno
Masatoshi
M
Teikyo University School of Medicine, Tokyo, Japan. mrsa@interlink.or.jp
Baba
Shunkichi
S
Mikawa
Haruki
H
Hara
Kohei
K
Matsumoto
Fumio
F
Kaga
Kimitaka
K
Nishimura
Tadao
T
Kobayashi
Toshimitsu
T
Furuya
Nobuhiko
N
Moriyama
Hiroshi
H
Okamoto
Yoshitaka
Y
Furukawa
Mituru
M
Yamanaka
Noboru
N
Matsushima
Toshiharu
T
Yoshizawa
Yasuyuki
Y
Kohno
Shigeru
S
Kobayashi
Kunihiko
K
Morikawa
Akihiro
A
Koizumi
Shoichi
S
Sunakawa
Keisuke
K
Inoue
Matsuhisa
M
Ubukata
Kimiko
K
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D006192:Haemophilus Infections / Q000382:microbiology; D006193:Haemophilus influenzae / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D008297:Male; D001936:Moraxella catarrhalis / Q000302:isolation & purification*; D045828:Moraxellaceae Infections / Q000382:microbiology; D009305:Nasopharynx / Q000187:drug effects / Q000382:microbiology*; D010033:Otitis Media / Q000188:drug therapy / Q000382:microbiology; D011008:Pneumococcal Infections / Q000382:microbiology; D016133:Polymerase Chain Reaction / Q000379:methods; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000302:isolation & purification*
D000890:Anti-Infective Agents